Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study (Q35189104)

7 August 2017

Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study (English)

1 reference

7 August 2017

1 reference

Dmowski WP

1

1 reference

7 August 2017

Radwanska E

2

1 reference

7 August 2017

Binor Z

3

1 reference

7 August 2017

Tummon I

4

1 reference

7 August 2017

Pepping P

5

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 March 1989

1 reference

7 August 2017

Fertility and Sterility

1 reference

7 August 2017

51

1 reference

7 August 2017

3

1 reference

7 August 2017

395-400

1 reference

Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Revised American Fertility Society classification of endometriosis: 1985

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Effects of danazol, gonadotropin-releasing hormone agonist, and estrogen/progestogen combination on experimental endometriosis in the ovariectomized rat

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

The interaction of human endometrial and myometrial steroid receptors with danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Danazol binding to steroid receptors in human uterine endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Danazol—a Synthetic Steroid Derivative with Interesting Physiologic Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Serum estradiol and danazol. I. Endometriosis response, side effects, administration interval, concurrent spironolactone and dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

Inhibition of Adrenal Steroidogenesis by Danazol in Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960543-5

7 January 2021

10.1016/S0015-0282(16)60543-5

Identifiers

DOI

0 references

1 reference